Coherus Oncology (CHRS) Cash from Financing Activities (2014 - 2026)

Coherus Oncology (CHRS) has 13 years of Cash from Financing Activities data on file, last reported at $53.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 20399.24% year-over-year to $53.6 million; the trailing twelve-month figure through Mar 2026 stood at -$219.9 million (down 16.86% YoY), and the FY2025 full-year result was -$273.7 million, down 46.39% from the prior year.
• Cash from Financing Activities climbed to $53.6 million in Q1 2026, from $8.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $54.3 million in Q2 2023 to a low of -$281.5 million in Q2 2025.
• A 5-year average of -$16.7 million and a median of $721000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities sank 445.93% in 2024 and surged 20399.24% in 2026, its largest moves.
• Tracing CHRS's Cash from Financing Activities over 5 years: stood at $6.6 million in 2022, then slumped by 94.45% to $366000.0 in 2023, then slumped by 36.89% to $231000.0 in 2024, then surged by 3398.27% to $8.1 million in 2025, then surged by 563.16% to $53.6 million in 2026.
• Business Quant data shows CHRS's Cash from Financing Activities at $53.6 million in Q1 2026, $8.1 million in Q4 2025, and $2000.0 in Q3 2025.